Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A
Life Sci. 1985 Jan 14;36(2):113-9. doi: 10.1016/0024-3205(85)90089-x.
Experiments were carried out to study the relationship between binding affinity to the benzodiazepine receptor and pharmacological activity, especially anti-anxiety activity, of clinically useful benzodiazepines. In the in vitro experiments, fludiazepam showed the highest affinity to the benzodiazepine receptor with 4 times more potency than that of diazepam, which paralleled the in vivo activity. Diazepam and nimetazepam also bound with high affinities as expected from their in vivo activities. On the contrary, medazepam and cloxazolam showed extremely low affinities and oxazolam showed no affinity, although they showed moderate in vivo activity. However, their metabolites were found to have both high affinity and in vivo activities. These results strongly suggest that in the case of medazepam, cloxazolam and oxazolam, their metabolites may bind to receptor sites in the brain and then elicit pharmacological action. This conclusion was supported by the fact that a good correlation between the binding affinity and the anti-anxiety activity of the tested compounds was observed.
开展了实验以研究临床上常用的苯二氮䓬类药物与苯二氮䓬受体的结合亲和力和药理活性(尤其是抗焦虑活性)之间的关系。在体外实验中,氟地西泮对苯二氮䓬受体表现出最高的亲和力,其效力是地西泮的4倍,这与体内活性平行。地西泮和硝甲西泮也如预期的那样以高亲和力结合,这与其体内活性相符。相反,美达西泮和氯恶唑仑表现出极低的亲和力,而恶唑仑则无亲和力,尽管它们在体内表现出中等活性。然而,发现它们的代谢产物具有高亲和力和体内活性。这些结果有力地表明,就美达西泮、氯恶唑仑和恶唑仑而言,它们的代谢产物可能与脑内的受体位点结合,进而引发药理作用。所测试化合物的结合亲和力与抗焦虑活性之间观察到良好的相关性,这一事实支持了该结论。